Decision: Favourable
Study Title:
A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-1
NREC Code:
22-NREC-CT-027
Decision:
Favourable
Meeting Date:
23/02/2022
Study Type:
CT application
Principal Investigator:
Dr John Quinn
PI Institution:
Beaumont Hospital
Sponsor:
GlaxoSmithKline